Mesoblast Limited (MESO): Price and Financial Metrics

Mesoblast Limited (MESO): $6.30

0.26 (+4.30%)

POWR Rating

Component Grades














  • MESO scores best on the Stability dimension, with a Stability rank ahead of 53.74% of US stocks.
  • MESO's strongest trending metric is Stability; it's been moving up over the last 48 weeks.
  • MESO ranks lowest in Quality; there it ranks in the 0th percentile.

MESO Stock Summary

  • Mesoblast Ltd's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than just 7.75% of US listed stocks.
  • With a price/sales ratio of 105.1, Mesoblast Ltd has a higher such ratio than 96.86% of stocks in our set.
  • As for revenue growth, note that MESO's revenue has grown -76.81% over the past 12 months; that beats the revenue growth of only 2.19% of US companies in our set.
  • If you're looking for stocks that are quantitatively similar to Mesoblast Ltd, a group of peers worth examining would be AU, AREC, IPHA, MUX, and ALV.
  • MESO's SEC filings can be seen here. And to visit Mesoblast Ltd's official web site, go to

MESO Valuation Summary

  • MESO's price/earnings ratio is -8.6; this is 123.56% lower than that of the median Healthcare stock.
  • Over the past 71 months, MESO's EV/EBIT ratio has gone down 3.7.
  • Over the past 71 months, MESO's EV/EBIT ratio has gone down 3.7.

Below are key valuation metrics over time for MESO.

Stock Date P/S P/B P/E EV/EBIT
MESO 2021-08-31 113.6 1.5 -8.6 -9.2
MESO 2021-08-30 139.5 1.4 -7.9 -8.0
MESO 2021-08-27 140.8 1.4 -7.9 -8.0
MESO 2021-08-26 139.8 1.4 -7.9 -8.0
MESO 2021-08-25 141.0 1.4 -7.9 -8.0
MESO 2021-08-24 138.1 1.4 -7.8 -7.9

MESO's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • MESO has a Quality Grade of F, ranking ahead of 1.01% of graded US stocks.
  • MESO's asset turnover comes in at 0.01 -- ranking 389th of 677 Pharmaceutical Products stocks.
  • STAB, OTLK, and AWH are the stocks whose asset turnover ratios are most correlated with MESO.

The table below shows MESO's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.010 1 -2.497
2021-03-31 0.009 1 -2.975
2020-12-31 0.024 1 -2.483
2020-09-30 0.023 1 -2.357
2020-06-30 0.047 1 -1.700
2020-06-30 0.047 1 -1.700

MESO Stock Price Chart Interactive Chart >

Price chart for MESO

MESO Price/Volume Stats

Current price $6.30 52-week high $19.45
Prev. close $6.04 52-week low $5.83
Day low $6.16 Volume 70,300
Day high $6.30 Avg. volume 341,390
50-day MA $6.90 Dividend yield N/A
200-day MA $8.53 Market Cap 817.36M

Mesoblast Limited (MESO) Company Bio

Mesoblast Ltd. has established a diverse portfolio of product candidates based on its proprietary allogeneic, off-the-shelf mesenchymal lineage cell-based technology, with multiple active Phase 3 clinical programs. Mesoblast's lead product candidates target major diseases with significant unmet medical needs despite existing therapies. These include chronic heart failure, chronic low back pain due to degenerative disc disease, and immune-mediated conditions such as acute graft versus host disease and biologic refractory rheumatoid arthritis. The company is based in Melbourne, Australia.

MESO Latest News Stream

Event/Time News Detail
Loading, please wait...

MESO Latest Social Stream

Loading social stream, please wait...

View Full MESO Social Stream

Latest MESO News From Around the Web

Below are the latest news stories about Mesoblast Ltd that investors may wish to consider to help them evaluate MESO as an investment opportunity.

Stem Cell Therapy Market the Next Big Thing, Major Giants - Anterogen, AlloSource, Mesoblast, ViaCyte, Anterogen

The latest research report covers market share, size, growth prospects, and includes future forecast for the Stem Cell Therapy market. This survey provides an industry assessment based on the precise calculations in the report. Market analysis is a comprehensive set

OpenPR | September 14, 2021

Top broker tips Mesoblast (ASX:MSB) share price to double in value

This biotech company''s shares have been tipped to shoot higher The post Top broker tips Mesoblast (ASX:MSB) share price to double in value appeared first on The Motley Fool Australia .

The Motley Fool Australia | September 9, 2021

Australian shares rise on miners, energy boost

Australian shares rose on Friday, boosted by energy and mining stocks, with sentiment aided by a strong finish on Wall Street overnight. The benchmark S&P/ASX 200 index climbed 0.4% by 0044 GMT. For the week so far, it is up 0.3%. Miners added 1%, a day after dropping nearly 3%, as it benefited from a rise in Chinese ironore futures. Global miner Rio Tinto jumped 2.3% and Orocobre Ltd advanced 4.8%. World''s largest miner BHP Group Ltd, which tumbled nearly 7% on Thursday on ex-dividend trade, added more than 1%. Energy stocks rose as much as 1.8% to hit a two-and-a-half-week high, underpinned by a rise in oil prices. Major oil and gas explorer Santos and Woodside Petroleum gained 2% and 1.8%, respectively. Supporting the jump in markets, the S&P 500 and Nasdaq eked out record finishes ...

Business Recorder | September 3, 2021

Why the Mesoblast (ASX:MSB) share price is down 21% this week

Shares in Mesoblast Limited (ASX: MSB) have taken a 21% dive this week following the release of its FY21 results. Here are the details. The information in this article contains general financial advice only and is authorised by The Rask Group Pty Ltd (ABN: 36 622 810 995). That means, the advice does not take into account your objectives, financial situation or needs. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. If you do not know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. Please take a moment to read our Financial Services Guide (FSG) . The post Why the Mesoblast (ASX:MSB) share price is down 21% this week appear...

Rask Australia (Media) | September 1, 2021

Mesoblast (ASX:MSB) shares rise as CEO reassures market on new FDA questions

Mesoblast''s CEO has reiterated the company is still working to gain FDA approval. The post Mesoblast (ASX:MSB) shares rise as CEO reassures market on new FDA questions appeared first on The Motley Fool Australia .

The Motley Fool Australia | September 1, 2021

Read More 'MESO' Stories Here

MESO Price Returns

1-mo -14.86%
3-mo -22.98%
6-mo -27.34%
1-year -63.33%
3-year -11.64%
5-year 42.53%
YTD -25.80%
2020 15.20%
2019 78.88%
2018 -29.45%
2017 9.16%
2016 -15.88%

Continue Researching MESO

Here are a few links from around the web to help you further your research on Mesoblast Ltd's stock as an investment opportunity:

Mesoblast Ltd (MESO) Stock Price | Nasdaq
Mesoblast Ltd (MESO) Stock Quote, History and News - Yahoo Finance
Mesoblast Ltd (MESO) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 1.0125 seconds.